Review



tramp c2ras prostate tumor cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC tramp c2ras prostate tumor cells
    Inhibitory effects of CM Oy-Lrp5 <t>on</t> <t>TRAMP-C2ras</t> prostate tumor cells. CN = control, CM = conditioned medium, Oy CM = osteocyte-derived CM, and Lrp5 = Lrp5 overexpression. The data are presented as mean ± S.D. (n = 3). The double asterisks indicate p < 0.01. ( a ) Inhibition of MTT-based viability of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . ( b ) Reduction in EdU-based proliferation by CM Oy-Lrp5 . Scale bar: 200 µm. ( c ) Increase in FRET efficiency in the vinculin biosensor by CM Oy-Lrp5 . The observed increase in FRET efficiency implies a decrease in vinculin-mediated molecular force at focal adhesions. Scale bar: 20 µm. ( d ) Inhibition of scratch-based migration of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . Scale bar: 200 µm. ( e ) Inhibition of transwell invasion by CM Oy-Lrp5 . Scale bar: 200 µm. ( f ) Reduction in the growth of 3D tumor spheroids by CM Oy-Lrp5 . Scale bar: 200 µm.
    Tramp C2ras Prostate Tumor Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 290 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tramp+c2ras+prostate+tumor+cells/TRAMP-C2/pmc12938517-43-0-4
    Average 96 stars, based on 290 article reviews
    tramp c2ras prostate tumor cells - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Induced Tumor-Suppressing (iTS) Cell-Based Approach for Protecting the Bone from Advanced Prostate Cancer"

    Article Title: Induced Tumor-Suppressing (iTS) Cell-Based Approach for Protecting the Bone from Advanced Prostate Cancer

    Journal: Biomolecules

    doi: 10.3390/biom16020240

    Inhibitory effects of CM Oy-Lrp5 on TRAMP-C2ras prostate tumor cells. CN = control, CM = conditioned medium, Oy CM = osteocyte-derived CM, and Lrp5 = Lrp5 overexpression. The data are presented as mean ± S.D. (n = 3). The double asterisks indicate p < 0.01. ( a ) Inhibition of MTT-based viability of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . ( b ) Reduction in EdU-based proliferation by CM Oy-Lrp5 . Scale bar: 200 µm. ( c ) Increase in FRET efficiency in the vinculin biosensor by CM Oy-Lrp5 . The observed increase in FRET efficiency implies a decrease in vinculin-mediated molecular force at focal adhesions. Scale bar: 20 µm. ( d ) Inhibition of scratch-based migration of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . Scale bar: 200 µm. ( e ) Inhibition of transwell invasion by CM Oy-Lrp5 . Scale bar: 200 µm. ( f ) Reduction in the growth of 3D tumor spheroids by CM Oy-Lrp5 . Scale bar: 200 µm.
    Figure Legend Snippet: Inhibitory effects of CM Oy-Lrp5 on TRAMP-C2ras prostate tumor cells. CN = control, CM = conditioned medium, Oy CM = osteocyte-derived CM, and Lrp5 = Lrp5 overexpression. The data are presented as mean ± S.D. (n = 3). The double asterisks indicate p < 0.01. ( a ) Inhibition of MTT-based viability of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . ( b ) Reduction in EdU-based proliferation by CM Oy-Lrp5 . Scale bar: 200 µm. ( c ) Increase in FRET efficiency in the vinculin biosensor by CM Oy-Lrp5 . The observed increase in FRET efficiency implies a decrease in vinculin-mediated molecular force at focal adhesions. Scale bar: 20 µm. ( d ) Inhibition of scratch-based migration of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . Scale bar: 200 µm. ( e ) Inhibition of transwell invasion by CM Oy-Lrp5 . Scale bar: 200 µm. ( f ) Reduction in the growth of 3D tumor spheroids by CM Oy-Lrp5 . Scale bar: 200 µm.

    Techniques Used: Control, Derivative Assay, Over Expression, Inhibition, Migration

    Related Articles

    Cell Culture:

    Article Title: Preventing tumor progression to the bone by induced tumor-suppressing MSCs
    Article Snippet: RAW264.7 pre-osteoclast cells (ATCC, Manassas, VA, USA) were grown in αMEM , . .. TRAMP-C2ras prostate tumor cells (ATCC) were cultured in DMEM/F-12 , and PC-3 human prostate cancer cells (ATCC) were cultured in RPMI-1640 (Gibco, Carlsbad, CA, USA) . .. Murine MSCs derived from the bone marrow of the C57BL/6 strain (Envigo RMS, Inc., Indianapolis, IN, USA) were cultured in MesenCult culture medium (Stem Cell Technology, Cambridge, MA, USA).

    Article Title: Generation of the tumor-suppressive secretome from tumor cells
    Article Snippet: EO771 mouse mammary tumor cells (CH3 BioSystems, Amherst, NY, USA), 4T1.2 mouse mammary tumor cells (obtained from Dr. R. Anderson at Peter MacCallum Cancer Institute, Melbourne, Australia), PANC-1 human pancreatic cancer cells (ATCC), and MCF-7 human estrogen receptor (ER)-positive breast cancer cells (ATCC) were cultured in DMEM (MT10013CV, Thermo Fisher Scientific). .. TRAMP-C2ras prostate tumor cells (ATCC) were cultured in DMEM/F-12 , and MDA-MB-231 human estrogen receptor (ER)-negative breast cancer cells and PC-3 human prostate cancer cells (ATCC) were cultured in RPMI-1640 (15040CV, Corning, Glendale, Arizona, USA) , . ..

    Article Title: Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs
    Article Snippet: .. TRAMP-C2ras prostate tumor cells (ATCC) were cultured in DMEM/F-12. .. Human epithelium cells (non-tumor immortalized control cells; KTB34-hTERT and KTB22-hTERT obtained from Dr. Nakshatri, Indiana University, IN, USA) were cultured in F12 and low glucose DMEM (3:1) with hydrocortisone (0.4 μg/mL, #H0888, Sigma), insulin (5 μg/mL, #I5500, Sigma) and EGF (20 ng/mL, #236-EG-200, R&D systems, Minneapolis, MN, USA).

    Article Title: Induced Tumor-Suppressing (iTS) Cell-Based Approach for Protecting the Bone from Advanced Prostate Cancer
    Article Snippet: .. TRAMP-C2ras prostate tumor cells (ATCC, CRL-2731) were cultured in DMEM/F-12 medium as described [ ]. .. EO771 mouse mammary tumor cells (CH3 BioSystems, Amherst, NY, USA), 4T1.2 mouse mammary tumor cells (obtained from Dr. R. Anderson at Peter MacCallum Cancer Institute, Melbourne, Australia), MDA-MB-231 breast cancer cells (ATCC, Manassas, VA, USA), and J774A.1 mouse monocytes were cultured in DMEM.

    Article Title: Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling
    Article Snippet: RAW264.7 pre-osteoclast cells (ATCC) and MC3T3 osteoblasts (Sigma, St. Louis, MO, USA) were grown in αMEM , . .. TRAMP-C2ras prostate tumor cells (ATCC) were cultured in DMEM/F-12. .. Mouse bone marrow-derived MSCs and human adipose-derived MSCs (Sigma) were grown in MSCBM (Lonza, Basel, Switzerland).

    Article Title: Therapeutic Insights into Low-intensity Vibration for Generating Induced Tumor-Suppressive Cells and Modulating the Bone Microenvironment
    Article Snippet: MDA-MB-231 breast cancer cells (ATCC; USA), MDA-MB-436 breast cancer cells (ATCC), 4T1.2 mouse mammary tumor cells (obtained from Dr. R. Anderson at Peter MacCallum Cancer Institute, Australia), MC3T3E1 osteoblasts (Sigma, USA) and murine MSCs isolated from the bone marrow of C57BL/6 mice were cultured in DMEM. .. TRAMP-C2ras prostate tumor cells (ATCC) were cultured in DMEM/F-12, and PC-3 human prostate cancer cells (ATCC), Jurkat T lymphocytes (ATCC), and PBMCs (Lonza, Switzerland) were cultured in RPMI1640 (Gibco, USA). .. RAW264.7 preosteoclast cells (ATCC) were grown in αMEM.

    Article Title: Induced Tumor-Suppressing (iTS) Cell-Based Approach for Protecting the Bone from Advanced Prostate Cancer
    Article Snippet: .. TRAMP-C2ras prostate tumor cells (ATCC, CRL-2731) were cultured in DMEM/F12 medium as described [30]. .. TRAMP-C2ras prostate tumor cells (ATCC, CRL-2731) were cultured in DMEM/F12 medium as described [30].

    Multiple Displacement Amplification:

    Article Title: Generation of the tumor-suppressive secretome from tumor cells
    Article Snippet: EO771 mouse mammary tumor cells (CH3 BioSystems, Amherst, NY, USA), 4T1.2 mouse mammary tumor cells (obtained from Dr. R. Anderson at Peter MacCallum Cancer Institute, Melbourne, Australia), PANC-1 human pancreatic cancer cells (ATCC), and MCF-7 human estrogen receptor (ER)-positive breast cancer cells (ATCC) were cultured in DMEM (MT10013CV, Thermo Fisher Scientific). .. TRAMP-C2ras prostate tumor cells (ATCC) were cultured in DMEM/F-12 , and MDA-MB-231 human estrogen receptor (ER)-negative breast cancer cells and PC-3 human prostate cancer cells (ATCC) were cultured in RPMI-1640 (15040CV, Corning, Glendale, Arizona, USA) , . ..



    Similar Products

    tramp c2ras prostate tumor cells  (ATCC)
    96
    ATCC tramp c2ras prostate tumor cells
    Inhibitory effects of CM Oy-Lrp5 <t>on</t> <t>TRAMP-C2ras</t> prostate tumor cells. CN = control, CM = conditioned medium, Oy CM = osteocyte-derived CM, and Lrp5 = Lrp5 overexpression. The data are presented as mean ± S.D. (n = 3). The double asterisks indicate p < 0.01. ( a ) Inhibition of MTT-based viability of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . ( b ) Reduction in EdU-based proliferation by CM Oy-Lrp5 . Scale bar: 200 µm. ( c ) Increase in FRET efficiency in the vinculin biosensor by CM Oy-Lrp5 . The observed increase in FRET efficiency implies a decrease in vinculin-mediated molecular force at focal adhesions. Scale bar: 20 µm. ( d ) Inhibition of scratch-based migration of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . Scale bar: 200 µm. ( e ) Inhibition of transwell invasion by CM Oy-Lrp5 . Scale bar: 200 µm. ( f ) Reduction in the growth of 3D tumor spheroids by CM Oy-Lrp5 . Scale bar: 200 µm.
    Tramp C2ras Prostate Tumor Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tramp+c2ras+prostate+tumor+cells/TRAMP-C2/pmc12938517-43-0-4
    Average 96 stars, based on 1 article reviews
    tramp c2ras prostate tumor cells - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    tramp c2ras murine prostate tumor cells  (ATCC)
    96
    ATCC tramp c2ras murine prostate tumor cells
    Inhibitory effects of CM Oy-Lrp5 <t>on</t> <t>TRAMP-C2ras</t> prostate tumor cells. CN = control, CM = conditioned medium, Oy CM = osteocyte-derived CM, and Lrp5 = Lrp5 overexpression. The data are presented as mean ± S.D. (n = 3). The double asterisks indicate p < 0.01. ( a ) Inhibition of MTT-based viability of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . ( b ) Reduction in EdU-based proliferation by CM Oy-Lrp5 . Scale bar: 200 µm. ( c ) Increase in FRET efficiency in the vinculin biosensor by CM Oy-Lrp5 . The observed increase in FRET efficiency implies a decrease in vinculin-mediated molecular force at focal adhesions. Scale bar: 20 µm. ( d ) Inhibition of scratch-based migration of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . Scale bar: 200 µm. ( e ) Inhibition of transwell invasion by CM Oy-Lrp5 . Scale bar: 200 µm. ( f ) Reduction in the growth of 3D tumor spheroids by CM Oy-Lrp5 . Scale bar: 200 µm.
    Tramp C2ras Murine Prostate Tumor Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tramp+c2ras+prostate+tumor+cells/Hanseniaspora+occidentalis+Smith+var%2E+occidentalis/pmc07828232-129-13-18
    Average 96 stars, based on 1 article reviews
    tramp c2ras murine prostate tumor cells - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Inhibitory effects of CM Oy-Lrp5 on TRAMP-C2ras prostate tumor cells. CN = control, CM = conditioned medium, Oy CM = osteocyte-derived CM, and Lrp5 = Lrp5 overexpression. The data are presented as mean ± S.D. (n = 3). The double asterisks indicate p < 0.01. ( a ) Inhibition of MTT-based viability of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . ( b ) Reduction in EdU-based proliferation by CM Oy-Lrp5 . Scale bar: 200 µm. ( c ) Increase in FRET efficiency in the vinculin biosensor by CM Oy-Lrp5 . The observed increase in FRET efficiency implies a decrease in vinculin-mediated molecular force at focal adhesions. Scale bar: 20 µm. ( d ) Inhibition of scratch-based migration of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . Scale bar: 200 µm. ( e ) Inhibition of transwell invasion by CM Oy-Lrp5 . Scale bar: 200 µm. ( f ) Reduction in the growth of 3D tumor spheroids by CM Oy-Lrp5 . Scale bar: 200 µm.

    Journal: Biomolecules

    Article Title: Induced Tumor-Suppressing (iTS) Cell-Based Approach for Protecting the Bone from Advanced Prostate Cancer

    doi: 10.3390/biom16020240

    Figure Lengend Snippet: Inhibitory effects of CM Oy-Lrp5 on TRAMP-C2ras prostate tumor cells. CN = control, CM = conditioned medium, Oy CM = osteocyte-derived CM, and Lrp5 = Lrp5 overexpression. The data are presented as mean ± S.D. (n = 3). The double asterisks indicate p < 0.01. ( a ) Inhibition of MTT-based viability of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . ( b ) Reduction in EdU-based proliferation by CM Oy-Lrp5 . Scale bar: 200 µm. ( c ) Increase in FRET efficiency in the vinculin biosensor by CM Oy-Lrp5 . The observed increase in FRET efficiency implies a decrease in vinculin-mediated molecular force at focal adhesions. Scale bar: 20 µm. ( d ) Inhibition of scratch-based migration of TRAMP-C2ras prostate tumor cells by CM Oy-Lrp5 . Scale bar: 200 µm. ( e ) Inhibition of transwell invasion by CM Oy-Lrp5 . Scale bar: 200 µm. ( f ) Reduction in the growth of 3D tumor spheroids by CM Oy-Lrp5 . Scale bar: 200 µm.

    Article Snippet: TRAMP-C2ras prostate tumor cells (ATCC, CRL-2731) were cultured in DMEM/F-12 medium as described [ ].

    Techniques: Control, Derivative Assay, Over Expression, Inhibition, Migration